Low to medium-low risk perception for dengue, chikungunya and Zika outbreaks by infectious diseases physicians in France, Western Europe.


Journal

BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562

Informations de publication

Date de publication:
31 Jul 2019
Historique:
received: 20 07 2018
accepted: 15 07 2019
entrez: 2 8 2019
pubmed: 2 8 2019
medline: 2 11 2019
Statut: epublish

Résumé

Many tropical countries are currently experiencing dengue (DEN), chikungunya (CHIK) and also more recently Zika (ZIKA) epidemics (particularly in Latin America). Although the risk of transmission and spread of these infections in temperate regions remains a controversial issue, vector-borne diseases have been widely reported in the media and have been the focus of preventive strategies by national and international policy-makers and public health authorities. In this context, we wanted to determine the extent of risk perception in infectious diseases (ID) physicians of the current and future risk of arboviral disease introduction, autochthonous case development and epidemic scenarios in France, Western Europe. To this aim, we developed an original standardized questionnaire survey which was disseminated by the French Infectious Diseases Society to ID physician members. We found that ID physicians perceived the risk of introduction and outbreak development of DEN, CHIK and ZIKA in France to be low to medium-low. Generalized Linear Model(s) identified medical school training, the extent of professional experience, and awareness of the French national plan regarding arboviral infections as significant predictors for lower risk perception among respondents. Despite the fact that arboviral diseases are increasingly being imported into France, sometimes resulting in sporadic autochtonous transmission, French ID physicians do not perceive the risk as high. Better communication and education targeting health professionals and citizens will be needed to enhance the effectiveness of the French national plan to prepare against arboviral diseases.

Sections du résumé

BACKGROUND BACKGROUND
Many tropical countries are currently experiencing dengue (DEN), chikungunya (CHIK) and also more recently Zika (ZIKA) epidemics (particularly in Latin America). Although the risk of transmission and spread of these infections in temperate regions remains a controversial issue, vector-borne diseases have been widely reported in the media and have been the focus of preventive strategies by national and international policy-makers and public health authorities. In this context, we wanted to determine the extent of risk perception in infectious diseases (ID) physicians of the current and future risk of arboviral disease introduction, autochthonous case development and epidemic scenarios in France, Western Europe.
METHODS METHODS
To this aim, we developed an original standardized questionnaire survey which was disseminated by the French Infectious Diseases Society to ID physician members.
RESULTS RESULTS
We found that ID physicians perceived the risk of introduction and outbreak development of DEN, CHIK and ZIKA in France to be low to medium-low. Generalized Linear Model(s) identified medical school training, the extent of professional experience, and awareness of the French national plan regarding arboviral infections as significant predictors for lower risk perception among respondents.
CONCLUSION CONCLUSIONS
Despite the fact that arboviral diseases are increasingly being imported into France, sometimes resulting in sporadic autochtonous transmission, French ID physicians do not perceive the risk as high. Better communication and education targeting health professionals and citizens will be needed to enhance the effectiveness of the French national plan to prepare against arboviral diseases.

Identifiants

pubmed: 31366341
doi: 10.1186/s12889-019-7317-9
pii: 10.1186/s12889-019-7317-9
pmc: PMC6889449
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1014

Subventions

Organisme : Labex
ID : ANR-11-LABX-0010
Organisme : Labex
ID : ANR-10-LABX-25-01

Références

Trop Dis Travel Med Vaccines. 2016 Jun 1;2:8
pubmed: 28883952
BMJ Open. 2012 Nov 28;2(6):null
pubmed: 23194955
Euro Surveill. 2009 Jun 25;14(25):null
pubmed: 19555595
PLoS Negl Trop Dis. 2015 Jun 16;9(6):e0003854
pubmed: 26079620
Int J Behav Med. 2009;16(1):30-40
pubmed: 19125335
Prev Med. 2011 Feb;52(2):178-81
pubmed: 21108960
J Gen Virol. 2016 Feb;97(2):269-273
pubmed: 26684466
Med Mal Infect. 2008 Jun;38 Suppl 2:S78-81
pubmed: 18598878
Trop Med Health. 2017 Sep 4;45:21
pubmed: 28878549
BMC Public Health. 2011 Jul 19;11:575
pubmed: 21771296
Emerg Infect Dis. 2014 Jun;20(6):1085-6
pubmed: 24856001
J Travel Med. 2018 Jul 1;25(1):
pubmed: 30016469
PLoS Negl Trop Dis. 2017 Jan 12;11(1):e0005254
pubmed: 28081120
Euro Surveill. 2016 Jun 9;21(23):
pubmed: 27311680
Sci Rep. 2018 Mar 15;8(1):4629
pubmed: 29545610
J Travel Med. 2016 Sep 05;23(6):
pubmed: 27601533
PLoS Negl Trop Dis. 2016 Nov 1;10(11):e0005081
pubmed: 27802275
Med Mal Infect. 2016 Sep;46(6):333-41
pubmed: 27297741
Lancet. 2016 Jan 23;387(10016):335-336
pubmed: 26777915
PLoS Negl Trop Dis. 2014 Dec 04;8(12):e3278
pubmed: 25474491
Bull Soc Pathol Exot. 2013 Aug;106(3):193-200
pubmed: 23765704
Lancet Infect Dis. 2014 Dec;14(12):1271-80
pubmed: 25172160
N Engl J Med. 2016 Feb 18;374(7):601-4
pubmed: 26761185
Lancet. 2016 May 28;387(10034):2183-5
pubmed: 27145708
Euro Surveill. 2013 Dec 12;18(50):20661
pubmed: 24342514
Emerg Infect Dis. 2016 May;22(5):913-5
pubmed: 27088243
Euro Surveill. 2011 Mar 03;16(9):null
pubmed: 21392489
Clin Microbiol Infect. 2010 Dec;16(12):1702-4
pubmed: 21040155
J Trop Med. 2012;2012:103679
pubmed: 22523497
Euro Surveill. 2016;21(8):30148
pubmed: 26939607
Euro Surveill. 2016 Jun 9;21(23):
pubmed: 27311329
Ann Dermatol Venereol. 2012 May;139(5):396-401; quiz 395, 402
pubmed: 22578347
Emerg Infect Dis. 2015 Apr;21(4):724-6
pubmed: 25811534
Trop Med Int Health. 2017 May;22(5):583-593
pubmed: 28294472
Euro Surveill. 2014 Feb 27;19(8):20718
pubmed: 24602277
Int J Infect Dis. 2016 Mar;44:11-5
pubmed: 26854199
BMC Public Health. 2011 Jan 03;11:2
pubmed: 21199571
Emerg Infect Dis. 2007 Feb;13(2):290-3
pubmed: 17479894
J Travel Med. 2018 Jan 1;25(1):
pubmed: 29669058
BMC Infect Dis. 2011 Jun 09;11:166
pubmed: 21658238
PLoS Negl Trop Dis. 2017 Jan 17;11(1):e0005255
pubmed: 28095405

Auteurs

Marion Le Tyrant (M)

UMR ESPACE 7300, CNRS, Aix Marseille University, Avignon Université, Université Nice Sophia-Antipolis, F-13545, Aix-en-Provence, France.
UMR MIVEGEC, IRD, CNRS, University of Montpellier, Centre IRD de Montpellier, F-34394, Montpellier, Cedex 5, France.

Daniel Bley (D)

UMR ESPACE 7300, CNRS, Aix Marseille University, Avignon Université, Université Nice Sophia-Antipolis, F-13545, Aix-en-Provence, France.

Catherine Leport (C)

Université Paris-Diderot, Inserm 1137, UMR 1137, 16, rue Henri-Huchard, 75870, Paris, Cedex 18, France.
Mission COREB Nationale, Assistance publique - Hôpitaux de Paris, 75004, Paris, France.

Serge Alfandari (S)

Service de réanimation et maladies infectieuses, Centre hospitalier de Tourcoing, Tourcoing, France.

Jean-François Guégan (JF)

UMR MIVEGEC, IRD, CNRS, University of Montpellier, Centre IRD de Montpellier, F-34394, Montpellier, Cedex 5, France. jean-francois.guegan@cirad.fr.
UMR ASTRE, INRA, Cirad, University of Montpellier, Campus international de Baillarguet, Montferrier-sur-Lez, F-34980, Montpellier, France. jean-francois.guegan@cirad.fr.
International U.N. programme FutureEarth, OneHealth global research programme, Montréal, Canada. jean-francois.guegan@cirad.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH